STTK Shattuck Labs Inc.

29.52
-2.48  -8%
Previous Close 32
Open 31.97
52 Week Low 17.51
52 Week High 59.5699
Market Cap $1,236,044,879
Shares 41,871,439
Float 22,543,320
Enterprise Value $1,036,259,341
Volume 119,786
Av. Daily Volume 158,278
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
SL-279252
Solid Tumors or Lymphomas
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
SL-172154
Ovarian Cancer
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
SL-172154
Head and Neck or Skin Squamous Cell Carcinoma
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, will participate in two upcoming conferences.

    Presentation Details
    Conference: 32nd Annual Cello Health Cancer Progress Conference
    Title: Multifunctional Soluble Biologics: Binders, Binders Everywhere
    Format: Panel discussion
    Date: May 5, 2021
    Time: 11:45 a.m. EST

    Conference: 17th Annual PEGS Boston Conference
    Title: Ranking Product Attributes to Select…

    AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, will participate in two upcoming conferences.

    Presentation Details

    Conference: 32nd Annual Cello Health Cancer Progress Conference

    Title: Multifunctional Soluble Biologics: Binders, Binders Everywhere

    Format: Panel discussion

    Date: May 5, 2021

    Time: 11:45 a.m. EST

    Conference: 17th Annual PEGS Boston Conference

    Title: Ranking Product Attributes to Select an Appropriate Expression Platform

    Format: Panel discussion

    Date: May 11, 2021

    Time: 12:20 p.m. EST

    The presentations and panel discussions will be available to registered conference attendees.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

     



    Primary Logo

    View Full Article Hide Full Article
  2. AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7th Annual Truist Securities Life Sciences Summit being held virtually May 4-5, 2021.

    Presentation Details
    Conference: 7th Annual Truist Securities Life Sciences Summit
    Format: Fireside chat with analyst Asthika Goonewardene
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer
    Date: May 5, 2021
    Time: 1:50 p.m. EST…

    AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7th Annual Truist Securities Life Sciences Summit being held virtually May 4-5, 2021.

    Presentation Details

    Conference: 7th Annual Truist Securities Life Sciences Summit

    Format: Fireside chat with analyst Asthika Goonewardene

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer

    Date: May 5, 2021

    Time: 1:50 p.m. EST

    Webcast Link: Available Here

    A live webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.



    Primary Logo

    View Full Article Hide Full Article
  3. AUSTIN, TX and DURHAM, NC, April 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.

    TIGIT blocking antibodies have shown encouraging clinical activity in combination with PD-1/L1 blocking antibodies in checkpoint naïve NSCLC, if PD-L1 expression is high. Thus, opportunities to broaden the utility of combined PD-1/TIGIT blockade may be evident in either checkpoint…

    AUSTIN, TX and DURHAM, NC, April 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.

    TIGIT blocking antibodies have shown encouraging clinical activity in combination with PD-1/L1 blocking antibodies in checkpoint naïve NSCLC, if PD-L1 expression is high. Thus, opportunities to broaden the utility of combined PD-1/TIGIT blockade may be evident in either checkpoint inhibitor (CPI) acquired resistant tumors, or tumors with low expression of PD-L1. Shattuck's presentation, titled "TNFSF14 (LIGHT) Co-Stimulation in Combination with Dual TIGIT/PD1 Checkpoint Inhibition (CPI) Induces Anti-Tumor Immunity in a CPI Acquired Resistance (AR) Model that Shares Transcriptional Similarities to Lung Cancer Patients Who Acquire Resistance to CPI," demonstrated that preclinically, SL-9258 (TIGIT-Fc-LIGHT) retained activity in a PD1 resistance model and outperformed dual checkpoint blockade with anti-PD1 and anti-TIGIT.

    The second poster highlighted expanded preclinical data from Shattuck's GADLEN™ platform. Titled "Antigen-specific targeting of tissue-resident gamma delta T cells with recombinant butyrophilin heterodimeric fusion proteins," the poster demonstrated a multi-layer analysis to uncover the gamma and delta TCR usage in tumors and the butyrophilin expression pattern guiding the design of GADLEN therapeutics, which will target hematologic malignancies and solid tumor indications.

    "These two presentations are great examples of the potential for the ARC platform, and the ability of our internal R&D teams to rapidly innovate in response to emerging clinical data," said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. "First generation TIGIT blocking antibodies and T cell engagers are providing clinical benefit across a variety of tumor indications, and both SL-9258 and the GADLEN platform were created to address the remaining unmet medical need in CPI acquired resistant tumors, and solid tumor indications, respectively."

    The posters will be available under the Events & Presentations section of the Company's website.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Forward Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, the potential for our proprietary ARC technology and GADLEN platform and the clinical benefit of TIGIT blocking antibodies and T cell engagers. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC")), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the recent and ongoing COVID-19 pandemic and associated shelter-in-place orders; expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our Phase 1 clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 16, 2021 with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.



    Primary Logo

    View Full Article Hide Full Article
  4. AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Needham's 20th Annual Healthcare Conference being held virtually April 12-15, 2021.

    Presentation Details
    Conference: 20th Annual Needham Healthcare Conference
    Format: Fireside chat with covering analyst, Chad Messer, Ph.D.
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer
    Date: April 14, 2021
    Time: 11:00 a.m. EST
    Webcast Link…

    AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Needham's 20th Annual Healthcare Conference being held virtually April 12-15, 2021.

    Presentation Details

    Conference: 20th Annual Needham Healthcare Conference

    Format: Fireside chat with covering analyst, Chad Messer, Ph.D.

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer

    Date: April 14, 2021

    Time: 11:00 a.m. EST

    Webcast Link: Available Here

    A live webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.



    Primary Logo

    View Full Article Hide Full Article
  5. AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the promotion of Andrew R. Neill to Chief Financial Officer from Vice President of Finance and Corporate Strategy.

    "Andrew is an incredibly experienced member of the Shattuck team and has made significant contributions to the company, including his key role in raising net proceeds of $330.5 million last year through our Series B and B-1 financings and initial public offering," said Taylor Schreiber, M.D., Ph.D., and Chief…

    AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the promotion of Andrew R. Neill to Chief Financial Officer from Vice President of Finance and Corporate Strategy.

    "Andrew is an incredibly experienced member of the Shattuck team and has made significant contributions to the company, including his key role in raising net proceeds of $330.5 million last year through our Series B and B-1 financings and initial public offering," said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. "Andrew's dedication and strategic impact will help Shattuck as we continue to advance our clinical-stage ARC compounds and GADLEN platform forward through clinical development."

    "As an early member of the Shattuck team, I am excited to continue building Shattuck and drive the company's growth from the CFO seat," said Mr. Neill. "I look forward to collaborating with all of our key stakeholders as we work to greatly improve treatment options for patients with cancer."

    Prior to joining Shattuck, Mr. Neill was the co-founder of Lumos Pharma, a biopharmaceutical company focused on developing therapeutics for genetic rare diseases. He holds a Master's in Business Administration, with majors in Health Care Management and Finance, from The Wharton School at the University of Pennsylvania, where he was a Kaiser Fellow. Andrew holds a Bachelor of Business Administration from Texas Christian University.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.



    Primary Logo

    View Full Article Hide Full Article
View All Shattuck Labs Inc. News